About SCOLR
Home Company Profile Press Releases Archives Schedule of Events Officers and Directors
December 2011 23: SCOLR Pharma, Inc. Announces Initial Shipments of its Nutritional Products23: SCOLR Pharma, Inc. Announces Third Quarter 2011 Financial Results July 2011 26: SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results June 2011 30: SCOLR Pharma, Inc. Announces Final Closing of Private Placement16: SCOLR Pharma, Inc. Announces Initial Closing of Private Placement May 2011 09: SCOLR Pharma, Inc. First Quarter 2011 Financial Results03: SCOLR PHARMA, INC. TO PRESENT AT TAGLICH BROTHERS 8TH ANNUAL SMALL CAP EQUITY CONFERENCE April 2011 28: SCOLR PHARMA, INC. TO PRESENT AT TAGLICH BROTHERS 8TH ANNUAL SMALL CAP EQUITY CONFERENCE26: SCOLR Pharma, Inc. Signs New Lease Amendment and Lowers Severance Amounts in Executive Contracts March 2011 29: SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs14: SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application February 2011 25: SCOLR Pharma, Inc. Retains Nicholas Hall & Company January 2011 13: SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011 December 2010 22: SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange November 2010 10: SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results September 2010 27: SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director August 2010 31: SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products10: SCOLR Pharma, Inc. Reports Second Quarter 2010 Financial Results June 2010 28: Nutritional Product Update and 2010 Sales Revenue Outlook May 2010 06: SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.03: SCOLR Pharma, Inc. Announces Receipt of Notice of Allowance of New U.S. Patent April 2010 29: SCOLR Pharma, Inc. Reports First Quarter 2010 Financial Results March 2010 24: SCOLR Pharma, Inc. Reports 2009 Full-Year Financial Results16: SCOLR Pharma, Acquires the Rights to Nuprin® from CVS December 2009 01: SCOLR Pharma, Inc. Licenses Dietary Supplements November 2009 30: SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards06: SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results September 2009 18: SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards August 2009 31: SCOLR Pharma, Inc. Appoints Stephen J. Turner as CEO07: SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results June 2009 29: SCOLR Pharma, Inc. Receives Notice of Non-Compliance from NYSE Amex for Continued Listing Requirements May 2009 01: First Quarter 2009 Financial Results Conference Call01: SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results April 2009 29: SCOLR Pharma, Inc. Schedules First Quarter 2009 Financial Results Conference Call for May 1, 2009 at 11:30 A.M. Eastern02: SCOLR Pharma, Inc. Announces Engagement of HealthPro as Financial Advisor March 2009 11: Fourth Quarter 2008 Financial Results Conference Call - March 11, 2009 at 11:30 A.M. Eastern11: SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results05: SCOLR Pharma, Inc. Schedules Fourth Quarter 2008 Financial Results Conference Call for March 11, 2009 at 11:30 A.M. Eastern February 2009 02: SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO January 2009 20: FDA Issues Complete Response Letter to SCOLR Pharma’s Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine December 2008 16: SCOLR Pharma, Inc. Announces Resignation of CEO Daniel O. Wilds November 2008 12: SCOLR Pharma, Inc. to Attend American Association of Pharmaceutical Scientists - AAPS - Annual Meeting and Exposition12: SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference07: Third Quarter 2008 Financial Results Conference Call07: SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results06: SCOLR Pharma, Inc. Announces Positive Top-Line Results From Pivotal Clinical Trial Evaluating Efficacy of Extended-Release Ibuprofen03: SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference October 2008 31: SCOLR Pharma, Inc. Schedules Third Quarter 2008 Financial Results Conference Call for November 7, 2008 at 11:30 A.M. Eastern09: SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen September 2008 26: SCOLR Pharma’s ANDA for 12-Hour CDT-Based Pseudoephedrine Accepted for Review by U.S. FDA24: SCOLR Pharma, Inc. Receives $3.1 Million Lease Termination Payment August 2008 07: Second Quarter 2008 Financial Results Conference Call; August 7, 2008 at 11:30 A.M. Eastern07: SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results06: SCOLR Pharma, Inc. Submits Abbreviated New Drug Application for a 12-hour CDT-based Pseudoephedrine Formulation July 2008 29: SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern01: SCOLR Pharma, Inc. Advances Extended-Release Ibuprofen with Initiation of Clinical Study June 2008 06: Results of the Annual Meeting of Stockholders of SCOLR Pharma, Inc. held on June 5, 2008 May 2008 02: SCOLR Pharma, Inc. Reports First Quarter 2008 Financial Results01: SCOLR Pharma, Inc. Enters into Lease Buyout Agreement April 2008 30: SCOLR Pharma, Inc. Announces Positive Progress for Lead Product25: SCOLR Pharma, Inc. Schedules First Quarter 2008 Financial Results March 2008 11: Q4 2007 Financial Results Webcast Link11: SCOLR Pharma, Inc. Reports Year End 2007 Financial Results04: SCOLR Pharma, Inc. Schedules Fourth Quarter and Fiscal 2007 Financial Results Conference Call for March 11, 2008 at 11:30 A.M. Eastern February 2008 14: SCOLR Pharma, Inc. to Present at the Roth Capital Partners Conference December 2007 05: SCOLR Pharma, Inc. Announces Extension of Research Agreement with Consumer Products Company to Co-Develop Novel Application of its CDT(R) Delivery Platform November 2007 29: SCOLR Pharma, Inc. Announces Pricing of Registered Direct Offering09: SCOLR Pharma, Inc. to Attend American Association of Pharmaceutical Scientists - AAPS - Annual Meeting and Exposition01: SCOLR Pharma, Inc. Initiates Pivotal Trials for 12-hour Ibuprofen October 2007 30: Third Quarter 2007 Financial Results Conference Call30: SCOLR Pharma, Inc. Reports Third Quarter 2007 Financial Results24: SCOLR Pharma, Inc. Schedules Third Quarter 2007 Financial Results Conference Call for October 30, 2007, at 11:30 A.M. Eastern23: SCOLR Pharma, Inc. and Dr. Reddy’s Laboratories Enter into Collaboration and License Agreement08: SCOLR Pharma, Inc. Announces the Addition of Jeff Reich, M.D. and Greg Weaver to its Board of Directors August 2007 29: SCOLR Pharma, Inc. to Present at the Roth Capital Partners 2007 New York Conference13: SCOLR Pharma, Inc. Announces New Board Member07: SCOLR Pharma, Inc. Reports Second Quarter 2007 Financial Results July 2007 31: SCOLR Pharma, Inc. Schedules Second Quarter 2007 Financial Results Conference Call for August 7, 2007, at 11:30 A.M. Eastern June 2007 29: SCOLR Pharma, Inc. Receives Notice from the American Stock Exchange Regarding Composition of its Board18: SCOLR Pharma, Inc. Issued Fifth Drug Delivery Patent for CDT(R) Drug Delivery Platform14: SCOLR Pharma, Inc. Announces New Product Launch with Alliance Partner May 2007 21: SCOLR Pharma, Inc. to Host Annual Stockholders Meeting08: SCOLR Pharma, Inc. Reports First Quarter 2007 Financial Results04: SCOLR Pharma, Inc. Schedules First Quarter 2007 Financial Results Conference Call for May 8, 2007 at 11:30 A.M. Eastern April 2007 30: SCOLR Pharma, Inc. to Present at the Taglich Brothers 4th Annual Small Cap Equity Conference17: SCOLR Pharma Announces Positive Ibuprofen Study Results and Status of Commercialization Program09: SCOLR Pharma, Inc. Starts CDT(R)-Fenofibrate Testing March 2007 15: SCOLR Pharma Says Wyeth Will Terminate Ibuprofen License12: SCOLR Pharma, Inc. Reports Year-End 2006 Financial Results09: SCOLR Pharma Announces Research Collaboration with BioCryst Pharmaceuticals01: SCOLR Announces Completion of 12 hour CDT-Pseudoephedrine ANDA Registration Batches, New Drug Development Targets February 2007 14: SCOLR Pharma, Inc. to Present at the Roth Capital Partners Conference06: SCOLR Pharma Announces Positive Results from Its Second 24 Hour CDT-Ondansetron Trial05: SCOLR Pharma to Present at the American Stock Exchange’s First Annual Healthcare Investor Conference January 2007 30: SCOLR Pharma Announces Receipt of Milestone Payment from Wyeth Consumer Healthcare November 2006 14: SCOLR Pharma Partner Introduces Three New Products Based on SCOLR Technology06: SCOLR Pharma, Inc. Reports Third Quarter 2006 Financial Results October 2006 25: SCOLR Reports Promising Results from Second CDT(R)-Raloxifene Trial24: SCOLR Commences CDT(R)-Ondansetron and Phenylephrine Testing20: SCOLR Pharma, Inc. to Attend American Association of Pharmaceutical Scientists - AAPS - Annual Meeting and Exposition September 2006 26: SCOLR Pharma Announces Achievement of Milestone With Wyeth Consumer Healthcare25: SCOLR Pharma, Inc. to Present at the UBS Global Life Sciences Conference on September 27, 200622: SCOLR Pharma Enters Research Collaboration to Co-Develop Novel Flu Application14: SCOLR Pharma, Inc. Engaged by Leading Consumer Products Company to Co-Develop Novel Application of its CDT(R) Delivery Platform August 2006 31: SCOLR Pharma, Inc. to Present at the Roth Capital Partners 2006 New York Conference07: SCOLR Pharma, Inc. Reports Second Quarter 2006 Financial Results June 2006 13: Results of the Annual Meeting of Stockholders of SCOLR Pharma, Inc. held on June 8, 200605: SCOLR Pharma’s Strategic Alliance’s Lead Product Introduction Gains Traction May 2006 09: SCOLR Pharma First Quarter 2006 Financial Results April 2006 24: SCOLR Pharma, Inc. to Present at the Taglich Brothers Third Annual Small Cap Equity Conference in New York on May 2, 200621: SCOLR Pharma, Inc. Announces Closing of $11.8 Million Financing19: SCOLR Pharma to Present at the UBS Global Specialty Pharmaceuticals Conference on April 24, 200618: SCOLR Pharma, Inc. to Raise $11.8 Million in Offering of Common Stock March 2006 23: SCOLR Pharma Reports Results for 200517: SCOLR Pharma Extends Form 10-K Filing; Company Expects to File Form 10-K Within Fifteen Days13: SCOLR Pharma to Present at the Academy of Pharmaceutical Science and Technology, Japan February 2006 28: SCOLR Pharma Announces First Shipment from Its Strategic Alliance16: SCOLR Pharma Reports Positive Ondansetron Clinical Results, New Drug Development Targets, and Revised Development Priorities December 2005 22: SCOLR Pharma Announces Worldwide Licensing Agreement with Wyeth Consumer Healthcare November 2005 16: SCOLR Pharma Retains Cameron Associates as Investor Relations Advisor14: SCOLR Pharma Reports Third Quarter and Nine-Month Results03: SCOLR Pharma to Present at Rodman & Renshaw Healthcare Conference in New York City02: SCOLR Pharma to Present at American Association of Pharmaceutical Scientists - AAPS - Annual Meeting and Exposition October 2005 27: SCOLR Pharma Files Shelf Registration Statement20: SCOLR Pharma and Perrigo Announce Strategic Alliance to Manufacture and Market CDT(R) Nutritional Products19: SCOLR Pharma, Inc. to Present at the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference in New York City September 2005 12: SCOLR Pharma, Inc. Issued Second Patent for Platform Used to Formulate Challenging Drugs August 2005 29: SCOLR Pharma Reports Raloxifene Study Validates Benefits of CDT(R) Platform for Challenging Drugs12: SCOLR Pharma Reports Second Quarter and Six-Month Results July 2005 12: SCOLR Pharma Appoints Hans Mueller, Ph.D., to Board of Directors June 2005 17: SCOLR Pharma, Inc. to Present Drug Delivery Research at Controlled Release Society Annual Meeting14: SCOLR Pharma Updates Development of Three CDT-based Pharmaceuticals06: SCOLR Pharma Secures Contract Manufacturer for 24 hour CDT Pseudoephedrine Tablets May 2005 25: SCOLR Pharma Initiates CDT-Raloxifene Pilot Testing23: SCOLR Pharma Initiates U.S. CDT-Ibuprofen Testing and Completes CDT-Pseudoephedrine Study Dosing17: SCOLR Pharma, Inc. to Present at Drug Delivery World Conference12: SCOLR Pharma Reports First Quarter Results for the Period Ended March 31, 2005 April 2005 27: SCOLR Pharma, Inc. to Present at Taglich Brothers Small Cap Conference in New York City22: SCOLR Pharma, Inc. to Present at Invest Northwest 2005 Conference15: SCOLR Pharma, Inc. Announces Effectiveness of Previously Filed Registration Statement for Resale of Common Stock13: SCOLR Pharma Adding Three Drug Targets To Its CDT® Drug Development Program05: Michael N. Taglich Appointed Chairman of SCOLR Pharma, Annual Meeting of Stockholders Announced March 2005 28: SCOLR Pharma Reports Positive Initial Clinical Results for CDT-Pseudoephedrine22: SCOLR Pharma Reports Results for 200407: SCOLR Pharma to Present at Value Rich Small-Cap Financial Conference & Exposition in Palm Beach, Florida01: SCOLR Pharma Announces the Start of its Extended Release CDT-Pseudoephedrine Human Trials February 2005 18: SCOLR Pharma to Present at Roth Capital Partners 17th Annual Growth Stock Conference in Dana Point, CA10: SCOLR Pharma Secures Contract Manufacturer for Raloxifene Tablets to Use in Q2 ‘05 Human Trials08: SCOLR Pharma Raises $15 Million in Equity Financing January 2005 24: SCOLR Pharma, Inc. Prepares to Initiate Two Trials05: SCOLR Pharma Expands Management Team with Appointment of Senior Vice President of Business and Legal Affairs, Chief Legal Officer December 2004 21: SCOLR Pharma, Inc. Files Provisional Patent for Rosiglitazone16: SCOLR Pharma Submits Investigational New Drug Application to the FDA for Its OTC CDT-Ibuprofen 01: Forum Alert: SCOLR Pharma, Inc. Presentation at Informed Investors Biotechnology & Healthcare Stocks Forum at the Crowne Plaza in Foster City on Dec. 7, 2004, 9:30 am PT November 2004 12: SCOLR Pharma Reports Third Quarter and Nine-Month Results12: SCOLR Pharma to Present at New York Society of Security Analysts Healthcare Conference in New York City08: SCOLR Pharma Reports Positive Results of Initial Animal Tests Utilizing Its Patented Amino Acid Technology on Poorly Soluble Molecules04: SCOLR Pharma to Present at American Association of Pharmaceutical Scientists — AAPS — Annual Conference and Exposition October 2004 22: SCOLR PHARMA TO PRESENT AT RODMAN & RENSHAW HEALTHCARE CONFERENCE IN NEW YORK CITY18: SCOLR Pharma Secures Contract Manufacturer for Pseudoephedrine Tablets for Use in Q1 ‘05 Human Trials04: SCOLR Pharma, Inc. Files Provisional Patents for Extended Release Ibuprofen and Raloxifene August 2004 13: SCOLR Pharma Reports Second Quarter and Six-Month Results02: SCOLR PHARMA, INC. SUBMITS FOURTH CDT® DRUG DELIVERY PATENT APPLICATION July 2004 30: International Drug Delivery Journal Review and Publication of SCOLR’s In Vitro-In Vivo Correlation -IVIVC- Study with CDT®30: SCOLR, Inc. Name Changed to SCOLR Pharma, Inc. 26: Cardinal Health to Manufacture Ibuprofen Tablets for Use by SCOLR, Inc. in Its Human Trials June 2004 28: SCOLR, Inc. Annual Meeting Overview — All Resolutions Passed21: ADVISORY/SCOLR, Inc. Presentation at American Stock Exchange Annual Online Healthcare & Biotech Investor Conference14: SCOLR, Inc. Presents Drug Delivery Research at Controlled Release Society Annual Meeting May 2004 24: SCOLR, INC.’s FORTUNE 100 CLIENT RETURNS TEST FORMULATION TO SCOLR18: SCOLR, Inc. Reports First Quarter Financials10: Cohen Independent Research Group Publishes Report on SCOLR, Inc. April 2004 30: SCOLR, INC. Sets Record Date for Annual Shareholder’s Meeting30: SCOLR, Inc. to Present at Rodman & Renshaw Techvest Global Healthcare Conference in London29: SCOLR, INC. IDENTIFIES ADDITIONAL EXTENDED RELEASE PRESCRIPTION AND OTC DRUG DEVELOPMENT TARGETS FOR ITS CDT® PLATFORM27: SCOLR, INC. TO PRESENT AT TAGLICH BROTHERS SMALL CAP CONFERENCE IN NEW YORK CITY20: SCOLR Appoints Additional Outside Board Members with Extensive Backgrounds in FDA-Regulatory, Pharmaceuticals & Finance; Wayne L. Pines & Michael Sorell, M.D. Join SCOLR’s Board05: SCOLR, Inc. Identifies Extended Release Ibuprofen as First Internal Development Target for Application of Its CDT Platform March 2004 23: SCOLR, INC. REPORTS 2003 YEAR-END RESULTS16: SCOLR, Inc. to Present at Invest Northwest Conference in Seattle February 2004 24: SCOLR, Inc. to Accelerate Drug Delivery Development with Definitive Agreement for $10.4 Million Private Placement of Common Stock and Warrants23: SCOLR’s CDT TM GLUCOSAMINE & CHONDROITIN NOW AVAILABLE IN GNC STORES06: American Stock Exchange Lists Common Stock of SCOLR, Inc.04: SCOLR, Inc. Approved for Listing on American Stock Exchange January 2004 26: SCOLR, Inc. Applies for Listing on the American Stock Exchange20: SCOLR, Inc. Closes Sale Of Probiotics Development And Manufacturing Business - Completes Transition To Drug Delivery Company05: SCOLR, Inc. To Sell Probiotics Development And Manufacturing Business To Complete Transition To A Drug Delivery Company December 2003 12: SCOLR, Inc. Expands Patented CDT TM Technology Product Line With Orders For Two New Products November 2003 21: SCOLR, INC. COMPLETES FEASIBILITY STUDY FOR FORTUNE 100 CLIENT12: SCOLR, Inc. Announces Appointments To Its Board Of Directors06: SCOLR Reports On Successful Presentations Made At AAPS (American Association of Pharmaceutical Scientists) Conference05: SCOLR Introduces Six New CDT® Nutritional Health Supplements October 2003 16: SCOLR, Inc. To Present Eight CDT® Drug Delivery Abstracts At American Association Of Pharmaceutical Scientists (AAPS) Annual Conference08: SCOLR’s New R&D Laboratory Facility Operational September 2003 02: SCOLR, Inc. Names David T. Howard Chairman Of The Board August 2003 18: SCOLR, Inc. Expands Board Of Directors07: SCOLR Expands Management Team to Accelerate Its Controlled Release Technology June 2003 27: SCOLR, INC. RETAINS DRUG DELIVERY LICENSING/STRATEGIC PLANNING CONSULTANT26: SCOLR, INC. COMPLETES $5.3 MILLION FINANCING OF SIX PERCENT CONVERTIBLE NOTES May 2003 27: SCOLR, INC. ANNUAL MEETING OVERVIEW– ADVANCEMENTS IN DRUG DELIVERY BUSINESS MODEL16: SCOLR, INC. ANNOUNCES FIRST QUARTER RESULTS–INCLUDING FIRST DRUG DELIVERY REVENUES April 2003 14: THIRD NATIONAL RETAIL CHAIN SIGNS TO CARRY SCOLR’s CDT® GLUCOSAMINE & CHONDROITIN03: SCOLR, INC. TO SHIP FIRST ORDER FOR CONTROLLED DELIVERY PRODUCT TO EUROPE February 2003 18: SCOLR, INC. TO SHIP FIRST ORDER12: SCOLR, INC. ISSUED PATENT FOR THIRD DRUG DELIVERY PLATFORM10: SCOLR’s FIRST CDT® PRODUCT TO BE CARRIED BY TWO NATIONAL RETAIL CHAINS07: LALLEMAND, INC. ACQUIRES SCOLR’s AGRICULTURAL BUSINESS January 2003 13: SCOLR, Inc. Introduces ReHydraid® Low-Osmolality Sports Drink at SupplySide West Show07: SCOLR, INC. ANNOUNCES MANUFACTURING AND DISTRIBUTION AGREEMENT FOR CDT® PRODUCTS
